GT Biopharma submits IND to FDA for GTB-3650 for CD33+ leukemia

GT Biopharma, Inc.

IND submitted for GTB-3650, a 2nd generation nanobody TriKE targeting CD33+ leukemia (relapsed/refractory AML and high-risk MDS).
Interim CEO Michael Breen says company aims to move GTB-3650 into the clinic expeditiously in 2024.
GTB-3650 is based on the proprietary TriKE NK cell engager platform licensed from University of Minnesota.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.